Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Saturday. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Stock Up 4.4 %

CTSO opened at $0.94 on Friday. The business’s fifty day simple moving average is $0.93 and its 200 day simple moving average is $1.01. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The firm has a market cap of $51.39 million, a P/E ratio of -2.61 and a beta of 0.57. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently added to or reduced their stakes in the company. CM Management LLC boosted its position in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares in the last quarter. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Atomi Financial Group Inc. bought a new position in Cytosorbents during the third quarter worth about $51,000. Finally, Sargent Investment Group LLC grew its stake in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.